(0.24%) 5 112.30 points
(0.21%) 38 319 points
(0.24%) 15 967 points
(-1.41%) $82.67
(3.80%) $1.996
(0.04%) $2 348.20
(-0.03%) $27.53
(3.53%) $954.65
(-0.18%) $0.933
(-0.31%) $10.99
(-0.42%) $0.797
(1.49%) $93.24
@ $55.32
発行日: 14 2月 2024 @ 01:06
リターン: -24.39%
前回のシグナル: 2月 13 - 23:30
前回のシグナル:
リターン: 0.69 %
Live Chart Being Loaded With Signals
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France...
Stats | |
---|---|
本日の出来高 | 87 044.00 |
平均出来高 | 419 558 |
時価総額 | 2.04B |
EPS | $0 ( 2024-02-27 ) |
次の収益日 | ( $0 ) 2024-05-07 |
Last Dividend | $0.300 ( 2010-06-11 ) |
Next Dividend | $0 ( N/A ) |
P/E | 16.09 |
ATR14 | $0.0530 (0.13%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-01 | Petersen Floyd F. | Sell | 500 | Common Stock |
2024-03-15 | Zhang Jack Y. | Buy | 722 046 | Common Stock |
2024-03-15 | Zhang Jack Y. | Sell | 408 721 | Common Stock |
2024-03-17 | Zhang Jack Y. | Sell | 15 768 | Common Stock |
2024-03-15 | Zhang Jack Y. | Buy | 310 930 | Common Stock |
INSIDER POWER |
---|
-2.74 |
Last 100 transactions |
Buy: 1 574 905 | Sell: 1 727 474 |
ボリューム 相関
Amphastar Pharmaceuticals 相関
10 最も負の相関 | |
---|---|
CSSEP | -0.95 |
NAKD | -0.95 |
ALXO | -0.95 |
MICS | -0.95 |
BLUE | -0.946 |
CBNK | -0.944 |
PMVP | -0.943 |
CMLS | -0.94 |
BWB | -0.94 |
FGBI | -0.939 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Amphastar Pharmaceuticals 相関 - 通貨/商品
Amphastar Pharmaceuticals 財務諸表
Annual | 2023 |
収益: | $644.40M |
総利益: | $343.97M (53.38 %) |
EPS: | $2.85 |
FY | 2023 |
収益: | $644.40M |
総利益: | $343.97M (53.38 %) |
EPS: | $2.85 |
FY | 2022 |
収益: | $498.99M |
総利益: | $248.86M (49.87 %) |
EPS: | $1.880 |
FY | 2021 |
収益: | $437.77M |
総利益: | $199.74M (45.63 %) |
EPS: | $1.350 |
Financial Reports:
No articles found.
Amphastar Pharmaceuticals Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.300 | 2009-06-11 |
Last Dividend | $0.300 | 2010-06-11 |
Next Dividend | $0 | N/A |
Payout Date | 2010-06-30 | |
Next Payout Date | N/A | |
# dividends | 2 | -- |
Total Paid Out | $0.600 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.66 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 4.09 | |
Div. Directional Score | 7.14 | -- |
Year | Amount | Yield |
---|---|---|
2009 | $0 | 0.00% |
2010 | $0 | 0.00% |
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.213 | 1.500 | 5.73 | 8.60 | [0 - 0.5] |
returnOnAssetsTTM | 0.0909 | 1.200 | 6.97 | 8.36 | [0 - 0.3] |
returnOnEquityTTM | 0.232 | 1.500 | 8.53 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 2.17 | 0.800 | 4.14 | 3.31 | [1 - 3] |
quickRatioTTM | 1.660 | 0.800 | 4.94 | 3.95 | [0.8 - 2.5] |
cashRatioTTM | 0.641 | 1.500 | 7.55 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.392 | -1.500 | 3.46 | -5.19 | [0 - 0.6] |
interestCoverageTTM | 9.50 | 1.000 | 7.59 | 7.59 | [3 - 30] |
operatingCashFlowPerShareTTM | 3.83 | 2.00 | 8.72 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 3.03 | 2.00 | 8.48 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.928 | -1.500 | 6.29 | -9.43 | [0 - 2.5] |
grossProfitMarginTTM | 0.541 | 1.000 | 4.32 | 4.32 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.294 | 1.000 | 6.12 | 6.12 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.309 | 1.000 | 9.39 | 9.39 | [0.2 - 2] |
assetTurnoverTTM | 0.426 | 0.800 | -0.494 | -0.395 | [0.5 - 2] |
Total Score | 10.19 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 14.33 | 1.000 | 8.65 | 0 | [1 - 100] |
returnOnEquityTTM | 0.232 | 2.50 | 9.06 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 3.03 | 2.00 | 8.99 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 3.83 | 2.00 | 8.72 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.191 | 1.500 | -2.06 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.285 | 1.000 | 5.38 | 0 | [0.1 - 0.5] |
Total Score | 4.09 |
Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。